A Pathophysiological Role of Plasma Indoxyl Sulfate in Patients with Heart Failure
Miki Imazu(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Toshisuke Morita(Toho University), Hiroyuki Takahama(Tohoku University), Masanori Asakura(National Cerebral and Cardiovascular Center), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Kazuhiro Shindo(National Cerebral and Cardiovascular Center), Hiroshi Asanuma(Meiji University of Integrative Medicine)
Cited by 11
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456